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Coronavirus Disease 2019 Diagnostics:
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With the coronavirus disease of 2019 (COVID-19) becoming a full-blown outbreak in Africa, coupled with
many other challenges faced on the African continent, it is apparent that Africa continues to need diagnostics to
enable case identification and recovery to this and future challenges. With the slow vaccination rates across the
continent, reliable diagnostic tests will be in demand, likely for years to come. Thus, access to reliable diag-
nostic tools to detect the severe acute respiratory syndrome of the coronavirus-2 (SARS-CoV-2), the virus
responsible for COVID-19, remain a critical pillar to monitor and contain new waves of COVID-19. Increasing
the local capacity to manufacture and roll-out vaccines and decentralized COVID-19 testing are paramount for
fighting the pandemic in Africa.
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The global weight of infectious diseases is heavier inAfrica compared with other continents. According to the
World Health Organization (WHO), about 50% of mortality
rates in children under 5 due to measles, diarrhea, malaria,
HIV, tuberculosis (TB), and pneumonia are in Africa (WHO,
2021). Similar mortality rates are also noted in African adults,
with an estimated 1.6 million annual deaths due to TB, HIV,
and malaria. Nonetheless, despite the escalating threat of
Coronavirus Disease of 2019 (COVID-19), Africa has ini-
tially faced a relatively low fraction of global COVID-19
mortalities (Dong et al., 2020). Data from 2020, generated
by the United Nations showed that Africa has 1.5% of the
world’s reported cases of COVID-19 and less than 0.1% of
the world’s deaths. This is largely due to the lockdown mea-
sures implemented early on by governments (Outlook, 2020).
To respond to COVID-19, many African Union member
states have been using a combination of containment and miti-
gation measures to delay a surge in cases that could over-
whelm the availability of hospital beds, while protecting the
medically vulnerable, such as the elderly and those with
comorbidities (Ondoa et al., 2020). However, the numbers
are likely underestimated due to limited testing. Specialized
laboratory facilities with skilled staff and expensive equip-
ment to undertake these tests are scarce in most African
countries. Centralized laboratories with testing facilities re-
quire samples to be transported and consistent access to
electricity, and systems to communicate the test results back
to patients. Thus, turnaround times may be suboptimal, re-
sulting in loss to follow-up, and a breakdown in implement-
ing the necessary isolation and contact tracing to contain
outbreaks. Point-of-care (PoC) or near-patient solutions, such
as rapid antigen tests, are preferable (WHO, 2020b; trials,
2020).
In general, the ability of any country to effectively con-
tain the COVID-19 pandemic depends on the capacity for
widespread testing, early diagnosis, tracking, and contact trac-
ing. However, there are different modalities of COVID-19
diagnositcs, where the applications are often misunder-
stood by the public (Page et al., 2020). The current gold stan-
dard of testing for severe acute respiratory syndrome of the
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coronavirus-2 (SARS-CoV-2) infection is reverse transcription/
polymerase chain reaction (RT-PCR), which relies on direct
detection of the viral genetic material in a sample from the
resipatory tract (Hellou et al., 2020). This sensitive test is
resource intensive and becoming increasingly inaccessible
for most African countries, particularly in rural settings. For
one to run a batch test for SARS-CoV-2, a laboratory fa-
cility with a biosafely level 2 rating is required with skilled
staff and expensive specialized equipment.
Furthermore, completing a COVID-19 RT-PCR test is a
multistep process that begins with sample collection, often
at a PoC that is far away from the country’s test center(s)
at central laboratories. The sample must then be carefully
packaged and transported, under a cold chain, to the distant
centralized testing site under conditions that protect sam-
ple integrity, and reduce risk of exposure. At the laboratory,
arduous sample preparation is required, including RNA
extraction for most RT-PCR platforms, followed by reac-
tion mix preparation and RT-PCR (Hellou et al., 2020).
The multistep, labor-intensive RT-PCR process results in
huge backlogs, severely slowing testing of suspected positive
cases, and limiting capacity for mass testing. Not only that, but
this tedious process poses a serious threat to undo the progress
made by African countries in reducing the risk of transmission,
possibly contributing to the current undersestimation of the
true burden of the disease, which is revealed by SARS-CoV-
2 seroprevalence studies, that is, studies measuring anti-
bodies against the virus, which indicate prior infection
(Arora et al., 2021). In fact, RT-PCR diagnostic capacity is
severely limited in most African countries, with the number
of qualified testing laboratories ranging between 1 and 3 in
40 African countries as of mid April 2020.
There are, however, ongoing efforts to improve testing
capacity in several countries, such as Kenya (Kobia, 2020).
Nevertheless, the level of testing in Africa varies as a
function of the economic status of the countries among other
factors such as political leadership, socioeconomic realities,
and stage of the pandemic. For example, South Africa, the
second largest economy on the continent, adopted a mass
screening strategy for SARS-CoV-2 in contrast to other
countries such as Uganda, which adopted a targeted
screening strategy focusing on a risk group (IPMU, 2020).
These factors, and the need for highly trained personnel,
limit the capacity of African countries to run COVID-19 tests,
further tipping the global imbalance against Africa. African
nations’ preparedness and competence in contact-tracing ca-
pacity during disease outbreaks is commendable. However,
Africa’s Achilles heel remains the limited access to diagnos-
tics, particularly locally manufactured RT-PCR-based tests.
Alternative SARS-CoV-2 tests that do not require nucleic acid
extraction, such as rapid antigen diagnostics for PoC testing,
exist (Muthamia et al., 2021). Other SARS-CoV-2 tests such
as near-patient solutions are preferred and one such test is a
PoC RT-PCR-based Xpert Xpress SARS-CoV-2 testing with a
fast turnaround (45 min) using small GeneXpert machines
(Cepheid, Sunnyvale, CA). The GeneXpert platform, already
in place for TB testing across most African countries, allows
the use of SARS-CoV-2 cartridges, however, drawbacks
include cost and scarcity of cartriges, as well as competition
with TB diagnosis (Nagura-Ikeda, 2020).
The major challenges of deploying alternative testing
modalities include test reliability (sensitivity and specificity),
supply chain, and fitness for utility. It is anticipated that in the
coming 3–6 months there will be several reliable antibody-
based tests in use in Africa. However, antibody-based sero-
logical tests only indicate prior exposure to SARS-CoV-2,
and do not diagnose current infection and transmission.
Rapid antigen tests are scalable and affordable alternatives to
RT-PCR. Thus, they allow for decentralized testing in rural and
resource-constrained communities. However, as new waves of
COVID-19 ravage the globe, the reliance on supply chain from
non-African developers needs to be urgently replaced with local
development and manufacturing of these rapid tests.
Meanwhile, global distribution of an efficacious vaccine
against SARS-CoV-2 is likely to be the most effective strat-
egy to curb transmission of the virus. At present, the prog-
ress in deploying antiviral drugs to treat SARS-CoV-2
infection remains slow and inadequate. In contrast, there are
currently over 100 vaccine candidates at different phases of
development and testing globally (WHO, 2020a) with at
least 10 in active clinical trials past phase 0 (Mullard, 2020),
and many already licensed and deployed.
As an imperative and at each stage of these clinical trials,
the safety of the vaccine is assessed by monitoring the rates of
adverse events, that is, dangerous side effects of the vaccines,
while the efficacy is determined usually by the rates of
moderate and severe COVID-19 disease. The first stage
(phase I), also known as ‘‘first-in-human’’ trials, aims to test
safety, and may include basic immunological assays to test
whether a vaccine induces a likely protective immune re-
sponse. These assays are based on the most up-to-date un-
derstanding of what a protective response may look like. It is
important, however, to emphasize that the collective under-
standing of correlates of protective immunity against COVID-
19 is still an emerging and evolving field. Importantly, this
phase does not test whether the vaccine is efficacious, that is,
whether the vaccine ‘‘works.’’ The second phase usually ex-
pands on the first phase, and may include additional metrics
such as determining the most effective dose of the vaccine.
Efficacy of the vaccine is only tested in phase IIb or phase
III, which usually extends to multiple sites, and tests whether
the vaccine can meaningfully prevent SARS-CoV-2 infections
and/or severe COVID-19 disease. In efficacy trials, uninfected
healthy volunteers are randomized into a control group that
does not receive the vaccine, and a parallel experimental group
that receives it. For a vaccine to be deemed efficacious, the rate
of infections in the vaccinated arm of the trial has to be sig-
nificantly lower than the control group in the same popula-
tion and setting. Here, reliable diagnostics to diagnose COVID-
19 are critical to definitively determine the rates of SARS-
CoV-2 infection, which necessitate serial testing during the
course of the trial to subsequently calculate vaccine efficacy.
These trials often require enrollment of hundreds or thousands
of volunteers, and have to take into account population dif-
ferences, which may influence vaccine efficacy.
Increasing the local manufacturing capacity of COVID-
19 vaccines is contingent on technology transfer from vac-
cine developers to vaccine manufacturing plants in Africa.
The Ad26.COV2.S vaccine by Johnson & Johnson is al-
ready being produced in Africa. Furthermore, on July 21st,
2021, Pfizer/BioNTech announced that it will share the in-
gredients for its vaccine for mass production in the Biovac
institute in Cape Town (Meldrum and Petesch, 2021).
However, to avoid the current situation of vaccine hoarding
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by high-income countries, the ultimate goal is to ramp up
the investment for local innovation, so that Africa leads its
own vaccine development and production.
Parallel clinical trials to test therapeutics against SARS-
CoV-2 have also taken place. In Africa, few countries have
participated in a COVID-19 clinical trial called ‘‘The Soli-
darity Trial’’ for potential antiviral therapies launched by the
WHO and partners (WHO, 2020b). This international clinical
trial compared four therapeutics against standard of care to
assess their effectiveness against COVID-19. The observed
limited participation by African countries may have been
caused by the reluctance of governments to facilitate national
trial participation, due to lack of biomedical infrastrucuture and
local capacity to provide regulatory vigilance and better gov-
ernance of clinical trials to protect clinical trial participants. As
of June 24, 2020, the first Africa assessment of COVID-19
vaccine candidate began in South Africa since South Africa
has the best developed medical infrastructure in Africa
(Clinical Trials Arena). Therefore, data from non-African
sites may not always be generalizable to African popula-
tions, and hence, trials in other African countries are needed.
With all these factors combined, the true extent of the spread
of COVID-19 in the continent is unclear and very hard to predict,
raising the risk of undetected community spread (Dong et al.,
2020; Arora et al., 2021). Furthermore, government responses to
COVID-19 that are blinded to the true pandemic realities on the
ground means that they may not be suitable or sufficient. For
instance, measures may not have been sufficiently strong to re-
flect the actual prevalence and position of communities on the
epidemic curve. Likewise, measures may be too stringent in
some contexts if identical risk is assumed countrywide in the
absence of mass surveillance data. Hence, limited diagnostic
capacity confounds candid evaluations of the governments’
COVID-19 responses, thus limiting the countries’ abili-
ties to deploy limited resources to maximum effectiveness.
Importantly, SARS-CoV-2 diagnostics need to be affordable
and widely accessible to test vaccine efficacy in Africa, es-
pecially if vaccine trials are conducted in African communities.
For a population density equivalent to almost 20% of the world
population, only 44 out of the 47 countries in the WHO Af-
rican region have at least one certified laboratory for SARS-
CoV-2 testing (at the start of the outbreak only two could do
so). Nevertheless, due to the centralized nature of these tests,
only a small percentage of the population has been tested.
According to the CDC, this is just over 0.1% of the African
population, in stark contrast to the Organization for Economic
Co-operation and Development (OECD) countries who on
average test 2.3% of their population. (https://africacdc.org/
covid-19/). Global supply chain constraints remain. The stan-
dard RT-PCR test kits are expensive, making the cost of large-
scale testing prohibitive for African countries.
As African countries struggle to combat many infectious
diseases, COVID-19 has overwhelmed global health systems,
including those of developed countries. In light of the global
performance surrounding COVID-19, better local solutions
depend on local scientific solutions. Africa will prevail against
the pandemic when the local science and research infra-
structures can directly inform health care practices and pol-
icies guiding control of infectious diseases outbreaks. This
should go hand in hand with increased procurement and
local manufacturing of diagnostic tests for COVID-19 to
allow for early case detection, contact tracing, and isolation.
The International Monetary Fund (IMF) projects that the
global economy has declined by around three percent in
2020 (Outlook, 2020). However, this should not hinder
African countries from strategically investing in science
and innovation, which will foster local economic growth.
The African Academy of Science, The African Institute for
Mathematical Sciences, and The Next Einstein Forum
initiative, are examples of several pan-African networks of
excellence in training and research, with a community of
scientists pushing forward several efforts in the global fight
against COVID-19.
Yet, funding is required to support African research in-
stitutes and science initiatives that are currently developing
in-house SARS-CoV-2 diagnostic tests, with the same ac-
curacy, reliability, and convenience, at a lower fraction of
the cost, in partnership with large international biopharma
availability of rapid local diagnosis will help to better
gauge the scale of infections and to respond accurately to
pandemics, both now and in the future. It will help Africa
tackle many problems at once, both at the health and
economic levels.
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